Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the effects of 2 weeks caffeine abstinence as compared to 2 weeks caffeine maintenance (300mg per day)on cognition and mood. Cerebral blood flow effects will also be assessed in a subset of participants. The role of caffeine abstinence/maintenance in the acute effects of caffeine will also be explored.
The current randomised, placebo-controlled, double-blind, parallel groups study aims to explore the behavioural effects of 2-weeks caffeine abstinence as well as establishing the role of abstinence in the effects of caffeine administration by administering caffeine or placebo to those in a state of chronic and acute abstinence. This research also aims to explore, in a subset of participants, the cerebral blood flow effects of caffeine abstinence and caffeine administration using Near Infrared Spectroscopy (NIRS). Cerebral blood flow will be measured both at rest and during performance of cognitive tasks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acute withdrawal | Experimental | Chronic intervention 100 mg caffeine capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15. |
|
| Acute caffeine-independent of withdrawal | Experimental | Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15. |
|
| Chronic abstinence | Experimental | Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15. |
|
| Acute caffeine-in state of withdrawal | Experimental | Chronic intervention of 100 mg caffeine capsule 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Dietary Supplement | Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15. |
| Measure | Description | Time Frame |
|---|---|---|
| Cognitive performance | Performance is assessed using COMPASS (Computerised Mental Performance Assessment System), which presents a battery of standard cognitive tasks assessing aspects of attention and memory. | 2 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Mood | Mood will be evaluated using Visual Analogue Scales administered using COMPASS. | 2 weeks |
| Cerebral haemodynamic | Cerebral blood flow will be measured in a subset of participants using Near Infrared Spectroscopy (NIRS). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Crystal Haskell, PhD | Northumbria University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brain, Performance and Nutrition Research Centre, Northumbria University | Newcastle upon Tyne | Tyne and Wear | NE1 8ST | United Kingdom |
Not provided
| Label | URL |
|---|---|
| COMPASS software | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D002110 | Caffeine |
| ID | Term |
|---|---|
| D014970 | Xanthines |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011688 | Purinones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Caffeine and Placebo | Dietary Supplement | 100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15. |
|
| Placebo and Caffeine | Dietary Supplement | Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15. |
|
| Caffeine | Dietary Supplement | Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15. |
|
| 2 weeks |
| Sleep | Quality of sleep will be measured using the Pitsburgh Sleep Quality Index (PSQI). | 2 weeks |
| Caffeine withdrawal | Symptoms of caffeine withdrawal will be measured using a Subjective and Somatic State Questionnaire. | 2 weeks |
| D011687 |
| Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |